FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30-POSITIVE (CD30+) CUTANEOUS T-CELL LYMPHOMA (CTCL)
2019 ◽
Vol 37
◽
pp. 286-288
◽
S.M. Horwitz
◽
J. Scarisbrick
◽
H.M. Prince
◽
S. Whittaker
◽
M. Duvic
◽
...